European Guidelines on Lipid Modification for Cardiovascular Modification

European Guidelines on Lipid Modification for Cardiovascular Modification

The emergence of a substantial body of evidence over the last few years has required new, up-to-date European Society of Cardiology and European Atherosclerosis Society ( E S C – E A S ) guidelines . Fenofibrate, a peroxisome proliferatoractivated receptor-α agonist, has been suggested as an important treatment opt ion in the management of dyslipidaemia owing to its effects on hypertriglyceridaemia and low high-density lipoproteincholesterol ( H D L – C ) concentrations.

Modern Medicine – Issue 3 2022